Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study

Infections during first‐line therapy for DLBCL are often associated with chemotherapy dose reductions and increased mortality. Systemic infections have also been suggested as beneficial promotors of immunological responses. However, whether there is an association between the timing of an infectious...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hematological oncology 2020-08, Vol.38 (3), p.318-325
Hauptverfasser: Clausen, Michael R., Ulrichsen, Sinna P., Juul, Maja B., Poulsen, Christian B., Iversen, Brian, Pedersen, Per T., Madsen, Jakob, Pedersen, Robert S., Josefsson, Pär L., Gørløv, Jette S., Nørgaard, Mette, d'Amore, Francesco
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 325
container_issue 3
container_start_page 318
container_title Hematological oncology
container_volume 38
creator Clausen, Michael R.
Ulrichsen, Sinna P.
Juul, Maja B.
Poulsen, Christian B.
Iversen, Brian
Pedersen, Per T.
Madsen, Jakob
Pedersen, Robert S.
Josefsson, Pär L.
Gørløv, Jette S.
Nørgaard, Mette
d'Amore, Francesco
description Infections during first‐line therapy for DLBCL are often associated with chemotherapy dose reductions and increased mortality. Systemic infections have also been suggested as beneficial promotors of immunological responses. However, whether there is an association between the timing of an infectious episode and outcome during treatment has not yet been clarified. We investigated how the occurrence and timing of infectious episodes during the first line of treatment for “de novo” DLBCL influenced patient outcome. We used data on DLBCL patients from the Danish Lymphoma Registry, the Danish National Patient Registry, and the Danish National Pathology Registry. Infections were categorized according to type (ICD‐10) and time of occurrence after treatment start. “Early” infections were defined as occurring between days 7 and 42 and “late” infections between days 100 and 150 from treatment start. Patients experiencing both “early and late” infections were categorized separately. We used multivariable Cox regression and Kaplan‐Meier estimates to assess the association between infections and survival adjusting for NCCN‐IPI, sex, comorbidity, and rituximab treatment. We identified 3546 patients, median age 65 years (IQR 56,73). Infectious episodes occurred in 1171 (33%) patients, of which 666 had “early,” 303 “late,” and 202 both “early and late” events. Patients without registered infections had a 5‐year overall survival (OS) rates of 74%. Those with “early,” “late,” or “early+late” had 5‐year OS of 65%, 62%, and 53%, respectively. Compared with patients without any registered infections, hazard rate ratios (HR) were 1.24 (95% CI 1.05‐1.47), 1.32 (95% CI 1.06–1.63), and 1.59 (95% CI 1.27‐2.00), respectively, in the multivariable model. We observed that infectious episodes during first‐line treatment for “de novo” DLBCL occurred in 44% of the patients. Irrespective of timing, patients with infectious episodes had an inferior outcome compared to those without. Outcome patterns were similar for patients registered with sepsis.
doi_str_mv 10.1002/hon.2734
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_hon_2734</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2385708393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3444-63bb62b8d9960c42912072fa35fc240dc980b0f29f56dc50edcbcd1addd9a3d43</originalsourceid><addsrcrecordid>eNqNkc-KFDEQh4Mo7rgKPoEEvAjSa3WS_pPj7qCusLge9Nykk8pMlu6kTbpZ5uYjePIBfRIzs-MKguCpQvJV5Zd8hDwv4awEYG-2wZ-xhosHZFWClEUJtXxIVsCatgDG2Ql5ktINQD6D9jE54YxxWTd8RX58imHjQ5qdpsltvLNOK6-RBkudt6hnF5ZEcXIpGEw0aL3E6PyGmuVQrItp_vnt--A80nmLUU07akOkxlm7JKSDihukFxnROAx02I3TNoyK5g16Tr3KF_hbZ5DqsA1xpmlezO4peWTVkPDZsZ6SL-_efl5fFlfX7z-sz68KzYUQRc37vmZ9a6SsQQsmSwYNs4pXVjMBRssWerBM2qo2ugI0utemVMYYqbgR_JS8ups7xfB1wTR3o0v7nMpjfnfHeFs10HLJM_ryL_QmLNHndB0TvGIMRNX-GahjSCmi7aboRhV3XQnd3lWXXXV7Vxl9cRy49COae_C3nAy8vgNusQ82aYdZzD2WbVZciqqp8wrKTLf_T6_dfPj4dVj8nFuLY6sbcPfPxN3l9cdD8l8gIsPd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435220458</pqid></control><display><type>article</type><title>Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study</title><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><creator>Clausen, Michael R. ; Ulrichsen, Sinna P. ; Juul, Maja B. ; Poulsen, Christian B. ; Iversen, Brian ; Pedersen, Per T. ; Madsen, Jakob ; Pedersen, Robert S. ; Josefsson, Pär L. ; Gørløv, Jette S. ; Nørgaard, Mette ; d'Amore, Francesco</creator><creatorcontrib>Clausen, Michael R. ; Ulrichsen, Sinna P. ; Juul, Maja B. ; Poulsen, Christian B. ; Iversen, Brian ; Pedersen, Per T. ; Madsen, Jakob ; Pedersen, Robert S. ; Josefsson, Pär L. ; Gørløv, Jette S. ; Nørgaard, Mette ; d'Amore, Francesco</creatorcontrib><description>Infections during first‐line therapy for DLBCL are often associated with chemotherapy dose reductions and increased mortality. Systemic infections have also been suggested as beneficial promotors of immunological responses. However, whether there is an association between the timing of an infectious episode and outcome during treatment has not yet been clarified. We investigated how the occurrence and timing of infectious episodes during the first line of treatment for “de novo” DLBCL influenced patient outcome. We used data on DLBCL patients from the Danish Lymphoma Registry, the Danish National Patient Registry, and the Danish National Pathology Registry. Infections were categorized according to type (ICD‐10) and time of occurrence after treatment start. “Early” infections were defined as occurring between days 7 and 42 and “late” infections between days 100 and 150 from treatment start. Patients experiencing both “early and late” infections were categorized separately. We used multivariable Cox regression and Kaplan‐Meier estimates to assess the association between infections and survival adjusting for NCCN‐IPI, sex, comorbidity, and rituximab treatment. We identified 3546 patients, median age 65 years (IQR 56,73). Infectious episodes occurred in 1171 (33%) patients, of which 666 had “early,” 303 “late,” and 202 both “early and late” events. Patients without registered infections had a 5‐year overall survival (OS) rates of 74%. Those with “early,” “late,” or “early+late” had 5‐year OS of 65%, 62%, and 53%, respectively. Compared with patients without any registered infections, hazard rate ratios (HR) were 1.24 (95% CI 1.05‐1.47), 1.32 (95% CI 1.06–1.63), and 1.59 (95% CI 1.27‐2.00), respectively, in the multivariable model. We observed that infectious episodes during first‐line treatment for “de novo” DLBCL occurred in 44% of the patients. Irrespective of timing, patients with infectious episodes had an inferior outcome compared to those without. Outcome patterns were similar for patients registered with sepsis.</description><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2734</identifier><identifier>PMID: 32239673</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Inc</publisher><subject>B-cell lymphoma ; Chemotherapy ; Cohort analysis ; diffuse large B‐cell lymphoma ; Hematology ; Immunology ; infection ; Infections ; Life Sciences &amp; Biomedicine ; Lymphoma ; Monoclonal antibodies ; Oncology ; Patients ; prognosis ; Rituximab ; Science &amp; Technology ; Sepsis ; Survival ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2020-08, Vol.38 (3), p.318-325</ispartof><rights>2020 John Wiley &amp; Sons Ltd</rights><rights>2020 John Wiley &amp; Sons Ltd.</rights><rights>2020 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>0</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000539457600001</woscitedreferencesoriginalsourcerecordid><cites>FETCH-LOGICAL-c3444-63bb62b8d9960c42912072fa35fc240dc980b0f29f56dc50edcbcd1addd9a3d43</cites><orcidid>0000-0003-3218-3633 ; 0000-0002-8821-7807 ; 0000-0001-6110-5891</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.2734$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.2734$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,28255,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32239673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Clausen, Michael R.</creatorcontrib><creatorcontrib>Ulrichsen, Sinna P.</creatorcontrib><creatorcontrib>Juul, Maja B.</creatorcontrib><creatorcontrib>Poulsen, Christian B.</creatorcontrib><creatorcontrib>Iversen, Brian</creatorcontrib><creatorcontrib>Pedersen, Per T.</creatorcontrib><creatorcontrib>Madsen, Jakob</creatorcontrib><creatorcontrib>Pedersen, Robert S.</creatorcontrib><creatorcontrib>Josefsson, Pär L.</creatorcontrib><creatorcontrib>Gørløv, Jette S.</creatorcontrib><creatorcontrib>Nørgaard, Mette</creatorcontrib><creatorcontrib>d'Amore, Francesco</creatorcontrib><title>Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study</title><title>Hematological oncology</title><addtitle>HEMATOL ONCOL</addtitle><addtitle>Hematol Oncol</addtitle><description>Infections during first‐line therapy for DLBCL are often associated with chemotherapy dose reductions and increased mortality. Systemic infections have also been suggested as beneficial promotors of immunological responses. However, whether there is an association between the timing of an infectious episode and outcome during treatment has not yet been clarified. We investigated how the occurrence and timing of infectious episodes during the first line of treatment for “de novo” DLBCL influenced patient outcome. We used data on DLBCL patients from the Danish Lymphoma Registry, the Danish National Patient Registry, and the Danish National Pathology Registry. Infections were categorized according to type (ICD‐10) and time of occurrence after treatment start. “Early” infections were defined as occurring between days 7 and 42 and “late” infections between days 100 and 150 from treatment start. Patients experiencing both “early and late” infections were categorized separately. We used multivariable Cox regression and Kaplan‐Meier estimates to assess the association between infections and survival adjusting for NCCN‐IPI, sex, comorbidity, and rituximab treatment. We identified 3546 patients, median age 65 years (IQR 56,73). Infectious episodes occurred in 1171 (33%) patients, of which 666 had “early,” 303 “late,” and 202 both “early and late” events. Patients without registered infections had a 5‐year overall survival (OS) rates of 74%. Those with “early,” “late,” or “early+late” had 5‐year OS of 65%, 62%, and 53%, respectively. Compared with patients without any registered infections, hazard rate ratios (HR) were 1.24 (95% CI 1.05‐1.47), 1.32 (95% CI 1.06–1.63), and 1.59 (95% CI 1.27‐2.00), respectively, in the multivariable model. We observed that infectious episodes during first‐line treatment for “de novo” DLBCL occurred in 44% of the patients. Irrespective of timing, patients with infectious episodes had an inferior outcome compared to those without. Outcome patterns were similar for patients registered with sepsis.</description><subject>B-cell lymphoma</subject><subject>Chemotherapy</subject><subject>Cohort analysis</subject><subject>diffuse large B‐cell lymphoma</subject><subject>Hematology</subject><subject>Immunology</subject><subject>infection</subject><subject>Infections</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Patients</subject><subject>prognosis</subject><subject>Rituximab</subject><subject>Science &amp; Technology</subject><subject>Sepsis</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNkc-KFDEQh4Mo7rgKPoEEvAjSa3WS_pPj7qCusLge9Nykk8pMlu6kTbpZ5uYjePIBfRIzs-MKguCpQvJV5Zd8hDwv4awEYG-2wZ-xhosHZFWClEUJtXxIVsCatgDG2Ql5ktINQD6D9jE54YxxWTd8RX58imHjQ5qdpsltvLNOK6-RBkudt6hnF5ZEcXIpGEw0aL3E6PyGmuVQrItp_vnt--A80nmLUU07akOkxlm7JKSDihukFxnROAx02I3TNoyK5g16Tr3KF_hbZ5DqsA1xpmlezO4peWTVkPDZsZ6SL-_efl5fFlfX7z-sz68KzYUQRc37vmZ9a6SsQQsmSwYNs4pXVjMBRssWerBM2qo2ugI0utemVMYYqbgR_JS8ups7xfB1wTR3o0v7nMpjfnfHeFs10HLJM_ryL_QmLNHndB0TvGIMRNX-GahjSCmi7aboRhV3XQnd3lWXXXV7Vxl9cRy49COae_C3nAy8vgNusQ82aYdZzD2WbVZciqqp8wrKTLf_T6_dfPj4dVj8nFuLY6sbcPfPxN3l9cdD8l8gIsPd</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Clausen, Michael R.</creator><creator>Ulrichsen, Sinna P.</creator><creator>Juul, Maja B.</creator><creator>Poulsen, Christian B.</creator><creator>Iversen, Brian</creator><creator>Pedersen, Per T.</creator><creator>Madsen, Jakob</creator><creator>Pedersen, Robert S.</creator><creator>Josefsson, Pär L.</creator><creator>Gørløv, Jette S.</creator><creator>Nørgaard, Mette</creator><creator>d'Amore, Francesco</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3218-3633</orcidid><orcidid>https://orcid.org/0000-0002-8821-7807</orcidid><orcidid>https://orcid.org/0000-0001-6110-5891</orcidid></search><sort><creationdate>202008</creationdate><title>Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study</title><author>Clausen, Michael R. ; Ulrichsen, Sinna P. ; Juul, Maja B. ; Poulsen, Christian B. ; Iversen, Brian ; Pedersen, Per T. ; Madsen, Jakob ; Pedersen, Robert S. ; Josefsson, Pär L. ; Gørløv, Jette S. ; Nørgaard, Mette ; d'Amore, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3444-63bb62b8d9960c42912072fa35fc240dc980b0f29f56dc50edcbcd1addd9a3d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>B-cell lymphoma</topic><topic>Chemotherapy</topic><topic>Cohort analysis</topic><topic>diffuse large B‐cell lymphoma</topic><topic>Hematology</topic><topic>Immunology</topic><topic>infection</topic><topic>Infections</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Patients</topic><topic>prognosis</topic><topic>Rituximab</topic><topic>Science &amp; Technology</topic><topic>Sepsis</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Clausen, Michael R.</creatorcontrib><creatorcontrib>Ulrichsen, Sinna P.</creatorcontrib><creatorcontrib>Juul, Maja B.</creatorcontrib><creatorcontrib>Poulsen, Christian B.</creatorcontrib><creatorcontrib>Iversen, Brian</creatorcontrib><creatorcontrib>Pedersen, Per T.</creatorcontrib><creatorcontrib>Madsen, Jakob</creatorcontrib><creatorcontrib>Pedersen, Robert S.</creatorcontrib><creatorcontrib>Josefsson, Pär L.</creatorcontrib><creatorcontrib>Gørløv, Jette S.</creatorcontrib><creatorcontrib>Nørgaard, Mette</creatorcontrib><creatorcontrib>d'Amore, Francesco</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Clausen, Michael R.</au><au>Ulrichsen, Sinna P.</au><au>Juul, Maja B.</au><au>Poulsen, Christian B.</au><au>Iversen, Brian</au><au>Pedersen, Per T.</au><au>Madsen, Jakob</au><au>Pedersen, Robert S.</au><au>Josefsson, Pär L.</au><au>Gørløv, Jette S.</au><au>Nørgaard, Mette</au><au>d'Amore, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study</atitle><jtitle>Hematological oncology</jtitle><stitle>HEMATOL ONCOL</stitle><addtitle>Hematol Oncol</addtitle><date>2020-08</date><risdate>2020</risdate><volume>38</volume><issue>3</issue><spage>318</spage><epage>325</epage><pages>318-325</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><abstract>Infections during first‐line therapy for DLBCL are often associated with chemotherapy dose reductions and increased mortality. Systemic infections have also been suggested as beneficial promotors of immunological responses. However, whether there is an association between the timing of an infectious episode and outcome during treatment has not yet been clarified. We investigated how the occurrence and timing of infectious episodes during the first line of treatment for “de novo” DLBCL influenced patient outcome. We used data on DLBCL patients from the Danish Lymphoma Registry, the Danish National Patient Registry, and the Danish National Pathology Registry. Infections were categorized according to type (ICD‐10) and time of occurrence after treatment start. “Early” infections were defined as occurring between days 7 and 42 and “late” infections between days 100 and 150 from treatment start. Patients experiencing both “early and late” infections were categorized separately. We used multivariable Cox regression and Kaplan‐Meier estimates to assess the association between infections and survival adjusting for NCCN‐IPI, sex, comorbidity, and rituximab treatment. We identified 3546 patients, median age 65 years (IQR 56,73). Infectious episodes occurred in 1171 (33%) patients, of which 666 had “early,” 303 “late,” and 202 both “early and late” events. Patients without registered infections had a 5‐year overall survival (OS) rates of 74%. Those with “early,” “late,” or “early+late” had 5‐year OS of 65%, 62%, and 53%, respectively. Compared with patients without any registered infections, hazard rate ratios (HR) were 1.24 (95% CI 1.05‐1.47), 1.32 (95% CI 1.06–1.63), and 1.59 (95% CI 1.27‐2.00), respectively, in the multivariable model. We observed that infectious episodes during first‐line treatment for “de novo” DLBCL occurred in 44% of the patients. Irrespective of timing, patients with infectious episodes had an inferior outcome compared to those without. Outcome patterns were similar for patients registered with sepsis.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>32239673</pmid><doi>10.1002/hon.2734</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-3218-3633</orcidid><orcidid>https://orcid.org/0000-0002-8821-7807</orcidid><orcidid>https://orcid.org/0000-0001-6110-5891</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0278-0232
ispartof Hematological oncology, 2020-08, Vol.38 (3), p.318-325
issn 0278-0232
1099-1069
language eng
recordid cdi_crossref_primary_10_1002_hon_2734
source Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />
subjects B-cell lymphoma
Chemotherapy
Cohort analysis
diffuse large B‐cell lymphoma
Hematology
Immunology
infection
Infections
Life Sciences & Biomedicine
Lymphoma
Monoclonal antibodies
Oncology
Patients
prognosis
Rituximab
Science & Technology
Sepsis
Survival
Targeted cancer therapy
title Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T20%3A00%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20infectious%20episodes%20occurring%20during%20first%E2%80%90line%20therapy%20for%20diffuse%20large%20B%E2%80%90cell%20lymphoma%20%E2%80%90%20A%20nationwide%20cohort%20study&rft.jtitle=Hematological%20oncology&rft.au=Clausen,%20Michael%20R.&rft.date=2020-08&rft.volume=38&rft.issue=3&rft.spage=318&rft.epage=325&rft.pages=318-325&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.2734&rft_dat=%3Cproquest_cross%3E2385708393%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2435220458&rft_id=info:pmid/32239673&rfr_iscdi=true